Table 4 Disease-modifying antirheumatic or immunossupressive drugs used by patients with rheumatoid arthritis at the time of the study
Hospitalization | No | Yes | P |
|---|---|---|---|
N = 215 | N = 54 | ||
Disease-modifying antirheumatic or immussupressive drugs | Â | Â | Â |
Without treatment | Â | Â | 1.000a |
 No n (%) | 210/215 (97.7) | 53/54 (98.1) |  |
 Yes n (%) | 5/215 (2.3) | 1/54 (1.9) |  |
Abatacept | Â | Â | 0.202a |
 No n (%) | 210/215 (97.7) | 51/54 (94.4) |  |
 Yes n (%) | 5/215 (2.3) | 3/54 (5.6) |  |
IL-17 inhibitors? |  |  | – |
 No n (%) | 215/215 (100.0) | 54/54 (100.0) |  |
IL12/23 inhibitors? | Â | Â | 1.000a |
 No n (%) | 214/215 (99.5) | 54/54 (100.0) |  |
 Yes n (%) | 1/215 (0.5) | 0/54 (0.0) |  |
TNF inhibitors | Â | Â | 0.014 |
 No n (%) | 147/215 (68.4) | 46/54 (85.2) |  |
 Yes n (%) | 68/215 (31.6) | 8/54 (14.8) |  |
Azathioprine | Â | Â | 0.040a |
 No n (%) | 215/215 (100.0) | 52/54 (96.3) |  |
 Yes n (%) | 0/215 (0.0) | 2/54 (3.7) |  |
Belimumab? |  |  | – |
 No n (%) | 215/215 (100.0) | 54/54 (100.0) |  |
Cyclophosphamide oral |  |  | – |
 No n (%) | 215/215 (100.0) | 54/54 (100.0) |  |
Ciclosporin |  |  | – |
 No n (%) | 215/215 (100.0) | 54/54 (100.0) |  |
Corticosteroids (oral) | Â | Â | 0.004a |
 No use | 149/215 (69.3) | 26/54 (48.1) |  |
 < 10 mg/day n (%) | 58/215 (27.0) | 20/54 (37.0) |  |
 ≥ 11 to 20 mg/day n (%) | 6/215 (2.8) | 7/54 (13.0) |  |
 ≥ 21 mg/day n (%) | 2/215 (0.9) | 1/54 (1.9) |  |
Hydroxychloroquine | Â | Â | 0.910 |
 No n (%) | 194/215 (90.2) | 49/54 (90.7) |  |
 Yes n (%) | 21/215 (9.8) | 5/54 (9.3) |  |
JAKi | Â | Â | 0.789a |
 No n (%) | 197/215 (91.6) | 49/54 (90.7) |  |
 Yes n (%) | 18/215 (8.4) | 5/54 (9.3) |  |
Leflunomide | Â | Â | 0.791 |
 No n (%) | 163/215 (75.8) | 40/54 (74.1) |  |
 Yes n (%) | 52/215 (24.2) | 14/54 (25.9) |  |
Methotrexate | Â | Â | 0.783 |
 No use n (%) | 117/211 (55.5) | 32/54 (59.3) |  |
 ≤ 20 mg/week n (%) | 77/211 (36.5) | 17/54 (31.5) |  |
 ≥ 21 mg/week n (%) | 17/211 (8.1) | 5/54 (9.3) |  |
Mycophenolatemofetil |  |  | – |
 No n (%) | 215/215 (100.0) | 54/54 (100.0) |  |
Cyclophosphamide pulsotherapy |  |  | – |
 No n (%) | 215/215 (100.0) | 54/54 (100.0) |  |
Methylprednisolone (pulsotherapy) |  |  | – |
 No n (%) | 215/215 (100.0) | 54/54 (100.0) |  |
Rituximab | Â | Â | 0.490a |
 No n (%) | 205/215 (95.3) | 50/54 (92.6) |  |
 Yes n (%) | 10/215 (4.7) | 4/54 (7.4) |  |
Sulfasalazine | Â | Â | 0.346a |
 No n (%) | 211/215 (98.1) | 52/54 (96.3) |  |
 Yes n (%) | 4/215 (1.9) | 2/54 (3.7) |  |
Tocilizumab | Â | Â | 0.687 |
 No n (%) | 191/215 (88.8) | 49/54 (90.7) |  |
 Yes n (%) | 24/215 (11.2) | 5/54 (9.3) |  |
Others | Â | Â | 0.283 |
 No n (%) | 183/215 (85.1) | 49/54 (90.7) |  |
 Yes n (%) | 32/215 (14.9) | 5/54 (9.3) |  |
scDMARD | Â | Â | 0.878 |
 No n (%) | 62/215 (28.8) | 15/54 (27.8) |  |
 Yes n (%) | 153/215 (71.2) | 39/54 (72.2) |  |
bDMARD | Â | Â | 0.083 |
 No n (%) | 107/215 (49.8) | 34/54 (63.0) |  |
 Yes n (%) | 108/215 (50.2) | 20/54 (37.0) |  |
Withdrawal | Â | Â | 0.010 |
 No n (%) | 168/215 (78.1) | 33/54 (61.1) |  |
 Yes n (%) | 47/215 (21.9) | 21/54 (38.9) |  |